Sorrento Therapeutics Inc

+0.07 (+4.64%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)638.98M
Current PEN/A
Forward PE N/A
2yr Forward PE 0.19
See more stats
Estimates Current Quarter
Revenue$17.83 Million
Adjusted EPS-$0.25
See more estimates
10-Day MA$1.50
50-Day MA$1.94
200-Day MA$4.93
See more pivots

Sorrento Therapeutics Inc Stock, NASDAQ:SRNE

4955 Directors Place, 4955 Directors Place, San Diego, California 92121
United States of America
Phone: +1.858.203.4100
Number of Employees: 799


Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.